Rhythm Pharmaceuticals is expected to announce top-line results from its ongoing Phase 3 trials exploring setmelanotide as an obesity treatment for patients with POMC and LEPR deficiency during the third quarter of 2019. The trials (NCT02896192 and NCT03287960) are still recruiting participants in the United…
A large-scale genetic screening identified 24 new genetic variants implicated in the distribution of body fat. Conducted by researchers from the Genetic Investigation of Anthropometric Traits consortium, the study adds new information on potential genes and mechanisms involved in the regulation and distribution of body fat. It may also…
Females have greater susceptibility than males to increased body fat content under a high-fat, high-sugar diet, a study in mice shows. This gender-specific effect is mediated by increased activation of mitochondrial pathways in adipose tissue, researchers found. The results were described in a study, “…
Kidney disease may be a primary manifestation of Alström syndrome. However, the development of renal problems may be nourished by the co-existence of other common disorders such diabetes, hypertension, and being insulin resistant, a single-center study suggests. The study, “Alström…
A new type of mutation affecting the BBS1 gene was identified in a patient diagnosed with Bardet-Biedl syndrome (BBS), a case report states. The study, “Retrotransposon insertion as a novel mutational event in Bardet-Biedl syndrome,” was published in the journal Molecular Genetics & Genomic Medicine.
With its first enrollee, Rhythm Pharmaceuticals has begun a pivotal Phase 3 trial to assess the therapeutic benefits of setmelanotide in patients with moderate-to-severe Bardet-Biedl syndrome…
Get regular updates delivered to your inbox.